BioCentury | Oct 5, 2009
Emerging Company Profile

Quantum Immunologics: Going to School

...Quantum Immunologics Inc. Tampa, Fla. Technology: Autologous dendritic cell immunotherapy containing oncofetal antigen/immature laminin receptor protein (OFA/iLRP...
BioCentury | Oct 5, 2009
Emerging Company Profile

Quantum Immunologics: Going to School

...it uses to target the cancer cells, a cell surface receptor known as oncofetal antigen/immature laminin receptor...
BioCentury | Jul 27, 2009
Clinical News

Dendritic cell vaccine: Phase I/II restarted

...Dendritic cell vaccine Business: Cancer Molecular target: Laminin receptor Description: Autologous dendritic cells exposed to immature laminin receptor...
BioCentury | May 19, 2008
Product Development

Metastatic target in the basement

...Although researchers discovered in 1984 that the laminin receptor precursor/laminin receptor (LRP/LR) is overexpressed in tumor tissue compared...
BioCentury | May 19, 2008
Clinical News

Affimed preclinical data

...number of invasive cells by 38% compared with untreated cells (p=0.03). The antibody against laminin receptor precursor/laminin receptor...
BioCentury | May 5, 2008
Clinical News

Anti-cancer immunotherapy: Phase I/II started

...have not responded to traditional therapies. The immunizing protein is an oncofetal antigen, or immature laminin receptor...
...Product: Anti-cancer immunotherapy Business: Cancer Molecular target: Laminin receptor Description: Autologous dendritic cells exposed to immature laminin receptor...
BioCentury | Apr 30, 2007
Clinical News

PCK3145: Phase I/II data

...Ambrilia Biopharma Inc. (TSX:AMB), Verdun, Quebec Product: PCK3145 Business: Cancer Molecular target: Laminin receptor Description: Synthetic peptide...
BioCentury | Jun 13, 2005
Clinical News

PCK3145: Phase IIa data

...a week dosing. Procyon BioPharma Inc. (TSE:PBP), Montreal, Quebec Product: PCK3145 Business: Cancer Molecular target: Laminin receptor...
Items per page:
1 - 8 of 8